DE69739035D1 - Zusammensetzungen und Methoden zur Behandlung von Infektionen unter Verwendung von Indolicidinanalogen - Google Patents
Zusammensetzungen und Methoden zur Behandlung von Infektionen unter Verwendung von IndolicidinanalogenInfo
- Publication number
- DE69739035D1 DE69739035D1 DE69739035T DE69739035T DE69739035D1 DE 69739035 D1 DE69739035 D1 DE 69739035D1 DE 69739035 T DE69739035 T DE 69739035T DE 69739035 T DE69739035 T DE 69739035T DE 69739035 D1 DE69739035 D1 DE 69739035D1
- Authority
- DE
- Germany
- Prior art keywords
- compositions
- methods
- treating infections
- indolicidin analogs
- indolicidin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0028—Disruption, e.g. by heat or ultrasounds, sonophysical or sonochemical activation, e.g. thermosensitive or heat-sensitive liposomes, disruption of calculi with a medicinal preparation and ultrasounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US2475496P | 1996-08-21 | 1996-08-21 | |
US3494997P | 1997-01-13 | 1997-01-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
DE69739035D1 true DE69739035D1 (de) | 2008-11-20 |
Family
ID=26698836
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69713112T Expired - Lifetime DE69713112T2 (de) | 1996-08-21 | 1997-08-21 | Zusammensetzungen und methoden zur behandlung von infektionen unter verwendung von indolicidin-analogen |
DE69739035T Expired - Lifetime DE69739035D1 (de) | 1996-08-21 | 1997-08-21 | Zusammensetzungen und Methoden zur Behandlung von Infektionen unter Verwendung von Indolicidinanalogen |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69713112T Expired - Lifetime DE69713112T2 (de) | 1996-08-21 | 1997-08-21 | Zusammensetzungen und methoden zur behandlung von infektionen unter verwendung von indolicidin-analogen |
Country Status (9)
Country | Link |
---|---|
US (4) | US6180604B1 (de) |
EP (1) | EP0925308B1 (de) |
JP (2) | JP2001500477A (de) |
AT (2) | ATE410441T1 (de) |
CA (1) | CA2263799A1 (de) |
DE (2) | DE69713112T2 (de) |
ES (2) | ES2178000T3 (de) |
HK (2) | HK1021824A1 (de) |
WO (1) | WO1998007745A2 (de) |
Families Citing this family (63)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IE20000918A1 (en) * | 1990-03-22 | 2001-05-30 | Sloan Kettering Inst Cancer | GP75 As a Tumor Vaccine for Melanoma |
US6180604B1 (en) | 1996-08-21 | 2001-01-30 | Micrologix Biotech Inc. | Compositions and methods for treating infections using analogues of indolicidin |
US6503881B2 (en) * | 1996-08-21 | 2003-01-07 | Micrologix Biotech Inc. | Compositions and methods for treating infections using cationic peptides alone or in combination with antibiotics |
WO1999043357A1 (en) * | 1998-02-25 | 1999-09-02 | Micrologix Biotech Inc. | Indolicidin and cationic peptides conjugated with polymers |
US6303575B1 (en) * | 1998-05-12 | 2001-10-16 | The Regents Of The University Of California | Indolicidin analogs and methods of using same |
AU4253799A (en) * | 1998-06-12 | 2000-01-05 | Micrologix Biotech, Inc. | Cancer therapy with cationic peptides |
US6444645B1 (en) * | 1998-06-18 | 2002-09-03 | The Regents Of The University Of California | Crosslink-stabilized indolicidin analogs |
US6288212B1 (en) * | 1998-08-28 | 2001-09-11 | The University Of British Columbia | Anti-endotoxic, antimicrobial cationic peptides and methods of use therefor |
BR9914922A (pt) * | 1998-10-30 | 2001-07-10 | Interlink Biotechnologies Llc | Métodos para reduzir a extensão de degradação de protease de uma proteìna aplicada a ou produzida por uma planta, para inibir o crescimento de um patógeno vegetal e para produzir uma planta, peptìdeo, molécula de ácido nucleico, segmento de ácido nucleico, construção de ácido nucleico, planta transgênica, semente, célula vegetal, e, composição para o uso na proteção de um peptìdeo, polipeptìdeo ou proteìna da degradação da protease. |
US6946261B1 (en) * | 1998-11-20 | 2005-09-20 | Migenix Inc. | Efficient methods for producing anti-microbial cationic peptides in host cells |
EP1185623A4 (de) * | 1999-03-03 | 2005-03-23 | Regents Board Of | Genetische und epigenetische manipulation von abc-transportern und ekto-phosphatasen zur vermittlung von arzneimittelresistenz und des verlustes von arzneimittelresistenz in biologischen systemen und verfahren zum nachweis von ekto-phosphatase-inhibitoren |
US6309633B1 (en) * | 1999-06-19 | 2001-10-30 | Nobex Corporation | Amphiphilic drug-oligomer conjugates with hydroyzable lipophile components and methods for making and using the same |
US6576224B1 (en) | 1999-07-06 | 2003-06-10 | Sinuspharma, Inc. | Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis |
US6429211B1 (en) * | 2000-05-23 | 2002-08-06 | Bayer Corporation | Praziquantel compounds for treating diseases due to Sarcocystis Neospora Toxoplasma and Isospora |
AU2001268512A1 (en) * | 2000-06-16 | 2002-01-02 | Hercules Incorporated | Chemically-modified peptides, compositions, and methods of production and use |
KR101201552B1 (ko) | 2000-10-18 | 2012-11-15 | 파마셋 인코포레이티드 | 바이러스 감염 및 비정상적인 세포 증식의 치료를 위한 변형된 뉴클레오시드 |
US7214364B2 (en) | 2000-12-27 | 2007-05-08 | Corus Pharma, Inc. | Inhalable aztreonam lysinate formulation for treatment and prevention of pulmonary bacterial infections |
ES2360692T3 (es) | 2000-12-27 | 2011-06-08 | Gilead Sciences, Inc. | Aztreonam inhalable para tratamiento y prevención de infecciones bacterianas pulmonares. |
US7115572B2 (en) * | 2001-03-29 | 2006-10-03 | Council Of Scientific And Industrial Research | Indolicidin analogs with anti-microbial activity |
US6759058B1 (en) * | 2001-04-25 | 2004-07-06 | Western Center For Drug Development College Of Pharmacy Western University Of Health Sciences | Enteric-coated proliposomal formulations for poorly water soluble drugs |
US8658202B2 (en) | 2001-04-25 | 2014-02-25 | Western University Of Health Sciences | Coated drug delivery formulations |
CN1516598A (zh) * | 2001-06-22 | 2004-07-28 | ��ͯ����ҽԺ | 抗菌肽 |
US6835536B2 (en) * | 2001-08-21 | 2004-12-28 | Micrologix Biotech Inc. | Antimicrobial cationic peptides and formulations thereof |
US6734165B2 (en) * | 2001-08-23 | 2004-05-11 | The Trustees Of Columbia University In The City Of New York | Method for re-sensitizing vancomycin resistant bacteria which selectively cleave a cell wall depsipeptide |
WO2003018619A2 (en) * | 2001-08-24 | 2003-03-06 | Micrologix Biotech Inc. | Antimicrobial and anti-inflammatory peptides |
US20030219854A1 (en) * | 2002-03-21 | 2003-11-27 | Micrologix Biotech Inc. | Methods for producing modified anti-infective peptides |
WO2003087815A2 (en) * | 2002-04-17 | 2003-10-23 | Novartis Ag | Method for the identification of inhibitors of the binding of are-containing mrn a and an hur protein |
WO2003091429A1 (fr) * | 2002-04-25 | 2003-11-06 | Toagosei Co.,Ltd. | Polypeptide microbicide et ses utilisations |
US7345018B2 (en) | 2002-04-25 | 2008-03-18 | Reception Aps | Method of treating side effects induced by therapeutic agents |
IL150907A (en) * | 2002-07-25 | 2007-07-04 | Stephan Cherkez | Process for the preparation of stable amorphous calcium pseudomonate |
SE0202613D0 (sv) * | 2002-09-04 | 2002-09-04 | Innate Pharmaceuticals Ab | Förfarande och prob för identifiering av ämnen som modifierar bakteriers virulens, som sådana identifierade ämnen samt deras användning |
US7238669B2 (en) * | 2002-09-11 | 2007-07-03 | The Curators Of The University Of Missouri | Phage-display peptides as novel antimicrobial agents against Haemophilus influenzae |
US20050245582A1 (en) * | 2002-09-12 | 2005-11-03 | The Hartz Mountain Corporation | High concentration topical insecticides containing pyrethroids |
EP1576150A4 (de) * | 2002-10-16 | 2006-05-03 | Univ Texas | Verfahren und zusammensetzungen zurerh hung der wirksamkeit biologisch aktiver inhaltsstoffe |
US7589078B2 (en) | 2003-02-19 | 2009-09-15 | Yale University | Anti-viral nucleoside analogs and methods for treating viral infections, especially HIV infections |
US20040260454A1 (en) * | 2003-06-11 | 2004-12-23 | Basir Otman A. | Vibro-acoustic engine diagnostic system |
US7189403B2 (en) * | 2003-06-30 | 2007-03-13 | Institut Pasteur | Attenuated flavivirus strains containing a mutated M-ectodomain and their applications |
US20050171063A1 (en) * | 2003-10-20 | 2005-08-04 | Pawan Malhotra | Use of phosphono derivatives as anti-malarials |
TR200603675T2 (tr) * | 2003-10-22 | 2007-01-22 | Council Of Scientific And Industrial Research | Seçilmiş amino asit-çinko komplekslerin anti-malaryal olarak kullanımı |
WO2005049819A1 (ja) * | 2003-10-29 | 2005-06-02 | Toagosei Co., Ltd. | 抗菌ペプチド及びその利用 |
JP2008500965A (ja) * | 2004-03-17 | 2008-01-17 | エムペックス・ファーマシューティカルズ・インコーポレーテッド | 細菌の排出ポンプ阻害剤の使用および投与 |
US7994225B2 (en) * | 2004-03-17 | 2011-08-09 | Rempex Pharmaceuticals, Inc. | Bacterial efflux pump inhibitors for the treatment of ophthalmic and otic infections |
US20050282755A1 (en) * | 2004-03-18 | 2005-12-22 | Ansata Therapeutics, Inc. | Compositions having antimicrobial activity and uses thereof |
CA2910494C (en) | 2004-07-19 | 2018-10-23 | Biocon Limited | Insulin-oligomer conjugates, formulations and uses thereof |
JP4507080B2 (ja) * | 2004-07-30 | 2010-07-21 | 東亞合成株式会社 | 抗菌ペプチド及びその利用 |
US7588885B2 (en) * | 2004-08-06 | 2009-09-15 | Chung Yuan Christian University | Use of biocistronic DNA constructs for identifying compounds that inhibit IRES-dependent translation |
WO2006036625A2 (en) * | 2004-09-24 | 2006-04-06 | The Hartz Mountain Corporation | Encapsulated pharmaceutical agents |
JP4730584B2 (ja) | 2004-12-06 | 2011-07-20 | 東亞合成株式会社 | 抗菌ペプチド及びその利用 |
US20090030179A1 (en) * | 2005-02-15 | 2009-01-29 | Toagosei Co., Ltd | Antimicrobial peptide and use thereof |
US7517852B2 (en) | 2005-07-28 | 2009-04-14 | Biosynexus Incorporated | Compositions and methods for treating bacteria |
WO2008150845A1 (en) * | 2007-05-31 | 2008-12-11 | Vanderbilt University | Screening for wnt pathway modulators and pyrvinium for the treatment of cance |
MX2010003979A (es) | 2007-10-16 | 2010-06-02 | Biocon Ltd | Composicion farmaceutica oralmente administrable y proceso para su preparacion. |
WO2009149278A1 (en) * | 2008-06-04 | 2009-12-10 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
JP2011195451A (ja) * | 2008-06-20 | 2011-10-06 | Fukuoka Univ | ペプチド |
US8773662B2 (en) * | 2010-07-22 | 2014-07-08 | Vuv Analytics, Inc. | Methods and apparatus for vacuum ultraviolet (VUV) or shorter wavelength circular dichroism spectroscopy |
PT2600869T (pt) * | 2010-08-05 | 2020-10-08 | Helperby Therapeutics Ltd | Combinação de um composto de pirroloquinolina e um agente antimicrobiano beta-lactâmico, mupirocina ou clorexidina |
CN102167731B (zh) * | 2011-02-10 | 2013-01-23 | 周逸明 | 一种固相多肽合成奥米加南的制备方法 |
US9487476B2 (en) | 2011-10-12 | 2016-11-08 | Yale University | Catechol diethers as potent anti-HIV agents |
EA034868B1 (ru) | 2013-09-12 | 2020-03-31 | Янссен Байофарма, Инк. | Пиридазиноновые соединения и их применение |
WO2015077057A1 (en) * | 2013-11-20 | 2015-05-28 | Texas Southern University | Methionine aminopeptidase inhibitors for treating infectious diseases |
RU2678985C2 (ru) * | 2017-02-06 | 2019-02-05 | Общество с ограниченной ответственностью "Научно-производственная фирма ВЕРТА" | Биоцидный пептид и препарат на его основе |
CN108721292B (zh) * | 2018-05-04 | 2022-04-01 | 中国疾病预防控制中心病毒病预防控制所 | 扑蛲灵在制备广谱抗冠状病毒药物中的应用 |
KR102433665B1 (ko) * | 2021-11-17 | 2022-08-19 | 주식회사 씨위드 | 인돌리시딘 유래 항균 펩타이드 및 이의 용도 |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2128617A (en) | 1982-10-06 | 1984-05-02 | Martti Vaara | Polypeptides for use in antibacterial therapy |
NZ237202A (en) | 1990-02-23 | 1994-01-26 | Bristol Myers Squibb Co | Composition containing beta-lactam antibiotic and cationic oligopeptide |
US5324716A (en) | 1991-06-14 | 1994-06-28 | Regents Of The University Of California | Broad spectrum antimicrobial compounds and methods of use |
US5547939A (en) | 1991-06-14 | 1996-08-20 | The Regents Of The University Of California | Broad spectrum antimicrobial compounds and methods of use |
US5593866A (en) | 1992-08-21 | 1997-01-14 | The University Of British Columbia | Cationic peptides and method for production |
US5681811A (en) | 1993-05-10 | 1997-10-28 | Protein Delivery, Inc. | Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same |
US5359030A (en) | 1993-05-10 | 1994-10-25 | Protein Delivery, Inc. | Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same |
CA2172245C (en) | 1993-09-22 | 2003-04-08 | Jonathan Cohen | Method of treating gram-negative bacterial infection by administration of bactericidal/permeability-increasing (bpi) protein |
KR960704524A (ko) * | 1993-10-25 | 1996-10-09 | 카롤 질레스피 | 디피신을 함유한 리포좀(liposomal defensins) |
EP0754050B1 (de) | 1994-01-14 | 2002-06-26 | XOMA Technology Ltd. | Anti gram positive bakterielle verfahren und mittel |
US5574017A (en) * | 1994-07-05 | 1996-11-12 | Gutheil; William G. | Antibacterial agents |
US5877274A (en) * | 1995-06-02 | 1999-03-02 | University Of British Columbia | Antimicrobial cationic peptides |
WO1997008199A2 (en) | 1995-08-23 | 1997-03-06 | University Of British Columbia | Antimicrobial cationic peptides and methods of screening for the same |
US5994308A (en) | 1996-02-28 | 1999-11-30 | Board Of Trustees Of Southern Illinois University | Broad spectrum antimicrobial peptides containing a tryptophan triplet and methods of use |
US6180604B1 (en) * | 1996-08-21 | 2001-01-30 | Micrologix Biotech Inc. | Compositions and methods for treating infections using analogues of indolicidin |
US6503881B2 (en) * | 1996-08-21 | 2003-01-07 | Micrologix Biotech Inc. | Compositions and methods for treating infections using cationic peptides alone or in combination with antibiotics |
US6551994B1 (en) | 1997-04-10 | 2003-04-22 | Mcgill University | Compounds and methods for inhibiting the interaction between α-catenin and β-catenin |
WO1999043357A1 (en) | 1998-02-25 | 1999-09-02 | Micrologix Biotech Inc. | Indolicidin and cationic peptides conjugated with polymers |
-
1997
- 1997-08-20 US US08/915,314 patent/US6180604B1/en not_active Expired - Lifetime
- 1997-08-21 AT AT01119148T patent/ATE410441T1/de not_active IP Right Cessation
- 1997-08-21 ES ES97941352T patent/ES2178000T3/es not_active Expired - Lifetime
- 1997-08-21 DE DE69713112T patent/DE69713112T2/de not_active Expired - Lifetime
- 1997-08-21 EP EP97941352A patent/EP0925308B1/de not_active Expired - Lifetime
- 1997-08-21 WO PCT/US1997/014779 patent/WO1998007745A2/en active IP Right Grant
- 1997-08-21 CA CA002263799A patent/CA2263799A1/en not_active Abandoned
- 1997-08-21 AT AT97941352T patent/ATE218579T1/de active
- 1997-08-21 JP JP10510994A patent/JP2001500477A/ja active Pending
- 1997-08-21 DE DE69739035T patent/DE69739035D1/de not_active Expired - Lifetime
- 1997-08-21 ES ES01119148T patent/ES2315252T3/es not_active Expired - Lifetime
-
1999
- 1999-12-30 HK HK99106212A patent/HK1021824A1/xx not_active IP Right Cessation
-
2000
- 2000-09-22 US US09/667,486 patent/US6538106B1/en not_active Expired - Fee Related
-
2002
- 2002-07-08 HK HK02105059.5A patent/HK1043475B/zh not_active IP Right Cessation
-
2003
- 2003-01-24 US US10/351,985 patent/US7390787B2/en not_active Expired - Fee Related
-
2004
- 2004-08-23 JP JP2004242925A patent/JP4073900B2/ja not_active Expired - Fee Related
-
2008
- 2008-03-28 US US12/058,500 patent/US20080242614A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
ATE218579T1 (de) | 2002-06-15 |
US7390787B2 (en) | 2008-06-24 |
US6538106B1 (en) | 2003-03-25 |
ES2178000T3 (es) | 2002-12-16 |
EP0925308B1 (de) | 2002-06-05 |
ES2315252T3 (es) | 2009-04-01 |
DE69713112D1 (de) | 2002-07-11 |
HK1021824A1 (en) | 2000-07-07 |
HK1043475A1 (en) | 2002-09-13 |
EP0925308A2 (de) | 1999-06-30 |
WO1998007745A2 (en) | 1998-02-26 |
ATE410441T1 (de) | 2008-10-15 |
CA2263799A1 (en) | 1998-02-26 |
DE69713112T2 (de) | 2003-01-30 |
JP4073900B2 (ja) | 2008-04-09 |
JP2001500477A (ja) | 2001-01-16 |
US20080242614A1 (en) | 2008-10-02 |
HK1043475B (zh) | 2009-07-03 |
WO1998007745A3 (en) | 1998-07-09 |
US20040009910A1 (en) | 2004-01-15 |
US6180604B1 (en) | 2001-01-30 |
JP2005225857A (ja) | 2005-08-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69713112D1 (de) | Zusammensetzungen und methoden zur behandlung von infektionen unter verwendung von indolicidin-analogen | |
ATE333464T1 (de) | Zusammensetzungen und verfahren zur behandlung von infektionen unter verwendung von kationischen peptiden allein oder in kombination mit antibiotika | |
ATE280826T1 (de) | Cc-chemokinzeptor c-c ckr-5, dessen derivate und verwendungen | |
MX9305729A (es) | Formulas de proteinas de liberacion sostenida. | |
ATE481480T1 (de) | Methoden und zusammensetzungen zur herstellung von polypeptiden | |
DE69823046D1 (de) | Praktische in vitro sialylierung von rekombinanten glykpproteinen | |
NZ227788A (en) | Peptide having growth hormone regulatory effects, and compositions | |
ATE352617T1 (de) | Lösliche polypeptidfraktionen des lag-3-proteins; verfahren zur herstellung; therapeutische zusamensetzung; antiidiotypischer antikörper | |
AU6020099A (en) | Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein | |
DE60023860D1 (de) | Verfahren zur herstellung von rekombinanten peptiden | |
DE69900756T2 (de) | Verwendung von hmg proteinen zur herstellung von arzneimitteln mit zytotoxischer wirkung | |
DK0896615T3 (da) | Peptid fra opløselig form af acetylcholinesterase, der er aktivt som calcium-kanal-modulator | |
DK525384D0 (da) | Praeparat paa basis af faktor viii til behandling af haemofili a inhibitorpatienter samt fremgangsmaade til fremstilling af et saadan praeparat | |
DE69735583D1 (de) | Semisynthetisches verfahren zur herstellung von didemninanalogen | |
EP1174439A3 (de) | Zusammensetzungen und Methoden zur Behandlung von Infektionen unter Verwendung von Indolicidinanalogen | |
ATE385805T1 (de) | Neue peptide | |
ATE452903T1 (de) | Modifizierte peptide und deren verwendung zur behandlung von autoimmunkrankheiten | |
DE59109235D1 (de) | Peptide des HIV-gag Proteins, ihre Herstellung und Verwendung | |
NO20014891D0 (no) | Fragmenter av virusprotein 2 eller 3 fra polyomavirus, anvendt for transportering av aktive ingredienser | |
SE9604439D0 (sv) | New receptor | |
ATE179182T1 (de) | Arginin ahnliche derivate als enzym-inhibitoren | |
HUP9601528A2 (hu) | Véralvadásgátló hatású peptidszármazékok és a vegyületeket tartalmazó gyógyszerkészítmények |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition |